Compare · AMGN vs IVVD
AMGN vs IVVD
Side-by-side comparison of Amgen Inc. (AMGN) and Invivyd Inc. (IVVD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and IVVD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $204.01B, about 881.1x IVVD ($231.5M).
- Over the past year, AMGN is up 36.5% and IVVD is down 44.6% - AMGN leads by 81.1 points.
- IVVD has been more active in the news (13 items in the past 4 weeks vs 7 for AMGN).
- AMGN has more recent analyst coverage (25 ratings vs 7 for IVVD).
- Company
- Amgen Inc.
- Invivyd Inc.
- Price
- $377.29-1.32%
- $0.79+1.31%
- Market cap
- $204.01B
- $231.5M
- 1M return
- -9.39%
- +7.54%
- 1Y return
- +36.48%
- -44.64%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2021
- News (4w)
- 7
- 13
- Recent ratings
- 25
- 7
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Latest AMGN
- AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
- IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Amgen downgraded by BMO Capital Markets with a new price target
- New insider Dittrich Thomas J.W. claimed ownership of 16,860 shares (SEC Form 3)
- AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE
- AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
- TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS
- SVP, Business Development Khosla Rachna exercised 1,252 shares at a strike of $162.60 and sold $1,346,499 worth of shares (3,252 units at $414.05), decreasing direct ownership by 24% to 6,404 units (SEC Form 4) to satisfy tax liability
- VP, Finance & CAO Busch Matthew C. was granted 730 shares, increasing direct ownership by 17% to 5,080 units (SEC Form 4)
- Director Ishrak Omar was granted 85 shares, increasing direct ownership by 1% to 7,486 units (SEC Form 4)
Latest IVVD
- Invivyd to Participate in Upcoming September Investor Conferences
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 4 filed by Director Sheffield Ian
- SEC Form 3 filed by new insider Sheffield Ian
- SEC Form 4 filed by Chief Executive Officer Elia Marc
- Invivyd Inc. filed SEC Form 8-K: Leadership Update, Other Events
- Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
- Chief Financial Officer Duke William E. converted options into 102,000 shares and sold $31,671 worth of shares (40,780 units at $0.78) as part of a pre-agreed trading plan, increasing direct ownership by 57% to 168,937 units (SEC Form 4) (for withholding tax)
- Chief Human Resources Officer Green Julie converted options into 102,000 shares and sold $31,671 worth of shares (40,780 units at $0.78) as part of a pre-agreed trading plan, increasing direct ownership by 57% to 168,937 units (SEC Form 4) to satisfy tax liability
- Chief Scientific Officer Allen Robert D. Iii sold $29,296 worth of shares (37,722 units at $0.78) as part of a pre-agreed trading plan and converted options into 102,000 shares, increasing direct ownership by 56% to 178,765 units (SEC Form 4) to satisfy withholding tax